MovDisordV3, Main, Exploration, bibRecord, 004B66

5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

Identifieur interne : 004B66 ( Main/Exploration ); précédent : 004B65; suivant : 004B67

5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

Auteurs : Susan H. Fox [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-11.

RBID : ISTEX:708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92

English descriptors

KwdEn :
- 5‐HT2C receptor, Aged, Aged, 80 and over, Antiparkinson Agents (pharmacology), Autoradiography, Binding Sites, Brain (metabolism), Dopamine Agonists (pharmacology), Dyskinesia, Drug-Induced (metabolism), Ergolines (pharmacology), Female, Humans, Male, Parkinson Disease (complications), Parkinson Disease (metabolism), Parkinson's disease, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin (drug effects), Receptors, Serotonin (metabolism), Serotonin Antagonists (pharmacology), Substantia Nigra (metabolism).
MESH :
- chemical , drug effects : Receptors, Serotonin.
- chemical , metabolism : Receptors, Serotonin.
- chemical , pharmacology : Antiparkinson Agents, Dopamine Agonists, Ergolines, Serotonin Antagonists.
- complications : Parkinson Disease.
- metabolism : Brain, Dyskinesia, Drug-Induced, Parkinson Disease, Substantia Nigra.
- Aged, Aged, 80 and over, Autoradiography, Binding Sites, Female, Humans, Male, Receptor, Serotonin, 5-HT2C.

Abstract

The involvement of abnormalities in nondopaminergic transmitter systems in Parkinson's disease is noteworthy because of the complications, such as dyskinesia, associated with long‐term dopamine replacement therapy. The output regions of the basal ganglia, the substantia nigra pars reticulata, and the medial segment of the globus pallidus are overactive in Parkinson's disease but underactive in dyskinesia. 5‐HT2C receptors are localized in these regions and are excitatory. A 5‐HT2C receptor binding assay using [3H]‐mesulergine and SB 200646A to define nonspecific binding was applied to postmortem tissue from patients with Parkinson's disease and from age‐matched control patients. [3H]‐mesulergine binding was increased in the substantia nigra pars reticulata by 108% in Parkinson's disease tissue as compared with control tissue. These data suggest abnormalities of 5‐HT2C transmission in the basal ganglia of patients with Parkinson's disease.

Url:

https://api.istex.fr/document/708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92/fulltext/pdf

DOI: 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C</idno>
<idno type="url">https://api.istex.fr/document/708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002967</idno>
<idno type="wicri:Area/Istex/Curation">002967</idno>
<idno type="wicri:Area/Istex/Checkpoint">003367</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Fox S:ht:c:receptor</idno>
<idno type="wicri:Area/Main/Merge">007464</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11104187</idno>
<idno type="wicri:Area/PubMed/Corpus">003E78</idno>
<idno type="wicri:Area/PubMed/Curation">003E78</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004066</idno>
<idno type="wicri:Area/Ncbi/Merge">000373</idno>
<idno type="wicri:Area/Ncbi/Curation">000373</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000373</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Fox S:ht:c:receptor</idno>
<idno type="wicri:Area/Main/Merge">007209</idno>
<idno type="wicri:Area/Main/Curation">004B66</idno>
<idno type="wicri:Area/Main/Exploration">004B66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, School of Biological Sciences, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Current Address: Walton Centre for Neurology and Neurosurgery, Fazakerley, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, School of Biological Sciences, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-11">2000-11</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1064">1064</biblScope>
<biblScope unit="page" to="1069">1069</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92</idno>
<idno type="DOI">10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C</idno>
<idno type="ArticleID">MDS1002</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5‐HT2C receptor</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Autoradiography</term>
<term>Binding Sites</term>
<term>Brain (metabolism)</term>
<term>Dopamine Agonists (pharmacology)</term>
<term>Dyskinesia, Drug-Induced (metabolism)</term>
<term>Ergolines (pharmacology)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Receptor, Serotonin, 5-HT2C</term>
<term>Receptors, Serotonin (drug effects)</term>
<term>Receptors, Serotonin (metabolism)</term>
<term>Serotonin Antagonists (pharmacology)</term>
<term>Substantia Nigra (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Ergolines</term>
<term>Serotonin Antagonists</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Autoradiography</term>
<term>Binding Sites</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Receptor, Serotonin, 5-HT2C</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The involvement of abnormalities in nondopaminergic transmitter systems in Parkinson's disease is noteworthy because of the complications, such as dyskinesia, associated with long‐term dopamine replacement therapy. The output regions of the basal ganglia, the substantia nigra pars reticulata, and the medial segment of the globus pallidus are overactive in Parkinson's disease but underactive in dyskinesia. 5‐HT2C receptors are localized in these regions and are excitatory. A 5‐HT2C receptor binding assay using [3H]‐mesulergine and SB 200646A to define nonspecific binding was applied to postmortem tissue from patients with Parkinson's disease and from age‐matched control patients. [3H]‐mesulergine binding was increased in the substantia nigra pars reticulata by 108% in Parkinson's disease tissue as compared with control tissue. These data suggest abnormalities of 5‐HT2C transmission in the basal ganglia of patients with Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</region>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:708CD573D496E33A8A12DEA87EE8B2DF9C7AFD92
   |texte=   5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.